September 16, 2024

Supplementary Fig. 5 from Anti-tumor efficacy of the novel KIT inhibitor IDRX-42 (formerly M4205) in patient- and cell line-derived xenograft models of gastrointestinal stromal tumor (GIST)

Key Points

Key points are not available for this paper at this time.

Abstract

Supplementary Fig. 5. Average number of apoptotic cells per treatment group in 10 high power fields assessed on (A) hematoxylin and eosin (H&E) staining and on (B) cleaved poly-ADP-ribose-polymerase (cPARP) staining.

Bookmark

Cite This Study

Sutter et al. (Mon,) studied this question.

synapsesocial.com/papers/68e586b5b6db643587522ced https://doi.org/https://doi.org/10.1158/1078-0432.27031858.v1

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Fig. 5 from Anti-tumor efficacy of the novel KIT inhibitor IDRX-42 (formerly M4205) in patient- and cell line-derived xenograft models of gastrointestinal stromal tumor (GIST)2024
2Supplementary Fig. 4 from Anti-tumor efficacy of the novel KIT inhibitor IDRX-42 (formerly M4205) in patient- and cell line-derived xenograft models of gastrointestinal stromal tumor (GIST)2024
3Supplementary Fig. 4 from Anti-tumor efficacy of the novel KIT inhibitor IDRX-42 (formerly M4205) in patient- and cell line-derived xenograft models of gastrointestinal stromal tumor (GIST)2024
4Supplementary Fig. 6 from Anti-tumor efficacy of the novel KIT inhibitor IDRX-42 (formerly M4205) in patient- and cell line-derived xenograft models of gastrointestinal stromal tumor (GIST)2024
5Supplementary Fig. 6 from Anti-tumor efficacy of the novel KIT inhibitor IDRX-42 (formerly M4205) in patient- and cell line-derived xenograft models of gastrointestinal stromal tumor (GIST)2024

Bookmark